ArticleBMC cancer2026
Effect of electronic cigarette aerosols on cisplatin resistance in head and neck cancer cells: a collaborative replication study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCisplatin chemoresistance is a critical challenge in treating head and neck squamous cell carcinoma (HNSCC). Previous research from Manyanga et al. (2021) suggested that e-cigarette (e-cig) aerosol, including formulations with and without nicotine, might increase cisplatin resistance in oral cancer cells. This multicenter replication study aimed to validate the findings and evaluate the oncologic impacts of e-cigarette use during chemotherapy.
methodsThis in vitro study utilized standardized and harmonized protocols across international laboratories to examine the effects of cigarette smoke (1R6F) and e-cig aerosols with different concentrations of nicotine (0, 12, and 20 mg/ml nicotine) on cisplatin sensitivity in HNSCC cell lines (SCC-25, FaDu, and UM-SCC-1). Aqueous extracts from 1R6F smoke and e-cig vapor were collected using a smoking and a vaping machine, respectively, following ISO20778:2018 and ISO20768:2018 puffing regimes. The smoke and vapor were collected in PBS and diluted to 10 puffs/5L for HNSCC cell treatment. Chemosensitivity, clonogenicity, DNA repair gene expression related to cisplatin-induced damage, and gene/protein expression of cisplatin transporters, were assessed by MTS, NRU, trypan blue exclusion, qRT-PCR, and Western blot assays, respectively.
resultsContrary to previous findings, exposure to e-cig aerosols did not significantly modulate cisplatin sensitivity in all cell lines. IC50 values, cytotoxicity assays, and clonogenic survival rates remained similar between cells treated with e-cig aerosols and those exposed to cisplatin alone. Analysis of gene and protein expression revealed occasional variations in the levels of cisplatin transporters and DNA repair mechanisms, but these changes were inconsistent.
conclusionsThis study did not fully substantiate previous claims that aerosols generated from e-cigarette, with and without nicotine, increase cisplatin resistance. The variability in gene and protein expression among different cell lines underscores the need for cautious interpretation and further investigation of the role of e-cigarette components in cancer treatment. These findings provide a critical perspective for shaping public health policies and clinical practices regarding e-cigarette use during chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.